CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Prdm16 Deficiency Leads to Age-Dependent Cardiac Hypertrophy, Adverse Remodeling, Mitochondrial Dysfunction, and Heart Failure Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation Positive recommendation for angiotensin receptor/neprilysin inhibitor: First medication approval for heart failure without "reduced ejection fraction" A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus Natriuretic Peptide-Guided Heart Failure Therapy After the GUIDE-IT Study Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

Original Research2018 Nov 7;39(42):3766-3776.

JOURNAL:Eur Heart J. Article Link

Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014

Szummer K, Wallentin L, Lindhagen L et al. Keywords: Registry , Myocardial infarction , Time-trends , Outcomes

FULL TEXT PDF